OR WAIT null SECS
CEO, Createrna Science and Technology, former Director of FDA’s Division of Pharmacometrics
March 03, 2022
Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.
February 01, 2012
Collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.